The Specimen Core provides part of the infrastructure support for Projects 1 - 5 as well as for future pilot and developmental projects. It has been designed to meet the needs of these projects plus serve as a stand-alone resource for collaborative efforts with other SPOREs. This Core will provide a well-organized and standardized system of specimen collection, storage, distribution and related clinical/research information dissemination that is based on over two decades of experience. There will be consistency and quality assurance in the pathological analysis of tissue specimens. The operations of this Core group into 5 components: 1. Clinical specimen acquisition (i.e. tissues, including those from surgery and the rapid autopsy program, serum, plasma and urine), processing, quality control, storage, distribution and database entry; 2. A development program to continually improve the quality and efficiency in biospecimen acquisition, processing and storage to increase the fidelity of specimens provided to the SPORE investigators; 3. Maintain 27 prostate cancer xenograft lines established by the Core team and make specimens available for biological study and/or perform pre-clinical studies for SPORE investigators and collaborators; 4. Laboratory services, including production of tissue microarrays, interpretation of immunohistology by urologic pathologists, production of specimen derivatives and perform PSA immunoassays for research; 5. An administrative program to obtain samples from minorities, prioritize the distribution of specimens, ensure patient confidentiality and compliance with IRB requirements, to continually improve quality control measures and to interact with other prostate cancer programs, including SPOREs and PO1s. Specimens from our repository, especially those from our rapid autopsy program (e.g. prostate cancer bone metastases) and our LuCaP series of prostate cancer xenografts have been and will continue to be distributed to other prostate cancer investigators on an international basis.
The performance of translational research mandates that investigators have ready access to well documented clinical specimens and relevant biological models. The Biospecimen Core directors have decades of experience in recognizing these needs and providing such services not only to local investigators but to those who request specimens on a world-wide basis. In this renewal, such interactions will continue even at a higher pace. This will truly enhance the translational aspects of our NW Prostate Cancer SPORE.
|Zhang, Ailin; Zhang, Jiawei; Plymate, Stephen et al. (2016) Classical and Non-Classical Roles for Pre-Receptor Control of DHT Metabolism in Prostate Cancer Progression. Horm Cancer 7:104-13|
|Uo, T; Dvinge, H; Sprenger, C C et al. (2016) Systematic and functional characterization of novel androgen receptor variants arising from alternative splicing in the ligand-binding domain. Oncogene :|
|Faltermeier, Claire M; Drake, Justin M; Clark, Peter M et al. (2016) Functional screen identifies kinases driving prostate cancer visceral and bone metastasis. Proc Natl Acad Sci U S A 113:E172-81|
|Lam, Hung-Ming; McMullin, Ryan; Nguyen, Holly et al. (2016) Characterization of an abiraterone ultraresponsive phenotype in castration-resistant prostate cancer patient-derived xenografts. Clin Cancer Res :|
|Saranchova, Iryna; Han, Jeffrey; Huang, Hui et al. (2016) Discovery of a Metastatic Immune Escape Mechanism Initiated by the Loss of Expression of the Tumour Biomarker Interleukin-33. Sci Rep 6:30555|
|Qu, Xiaoyu; Jeldres, Claudio; Glaskova, Lena et al. (2016) Identification of Combinatorial Genomic Abnormalities Associated with Prostate Cancer Early Recurrence. J Mol Diagn 18:215-24|
|Gulati, Roman; Cheng, Heather H; Lange, Paul H et al. (2016) Screening men at increased risk for prostate cancer diagnosis: Model estimates of benefits and harms. Cancer Epidemiol Biomarkers Prev :|
|Shui, Irene M; Kolb, Suzanne; Hanson, Christi et al. (2016) Trichomonas vaginalis infection and risk of advanced prostate cancer. Prostate 76:620-3|
|Coleman, Daniel J; Van Hook, Kathryn; King, Carly J et al. (2016) Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor. Oncotarget 7:40690-40703|
|Pritchard, Colin C; Mateo, Joaquin; Walsh, Michael F et al. (2016) Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med 375:443-53|
Showing the most recent 10 out of 323 publications